Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Intelligence coverage: 60%
Basic profile, financials, and market data are shown below. Deep research is building in the background.
AI confidence 70% · prior close shown (market closed)
Avalo Therapeutics, Inc. shows decelerating business momentum based on AlphaOS pipeline evidence.
3 signals not yet derived from pipeline evidence
Pipeline evidence · 0d ago
AVTX's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on AVTX.
Free accounts see more of this; Premium sees all of it.
Reported figures for Avalo Therapeutics, Inc. — research only, not investment advice.
Updated
What happened recently for Avalo Therapeutics, Inc. (AVTX) — events, not interpretation.
Research & analysis only — not investment advice.
Investment snapshot
AVTX's AI investment thesis
Upgrade to Premium for AVTX's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$16.51
Market cap
$885.43M
Profitable
No
Revenue $27.81M
Net income
$-78.26M
FY Dec 31, 2017
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for Avalo Therapeutics, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow Avalo Therapeutics, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.